Exact Sciences Corporation (NASDAQ:EXAS)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a report released on Thursday. They currently have a $45.00 price objective on the medical research company’s stock. Canaccord Genuity’s target price indicates a potential upside of 5.98% from the stock’s previous close.

Several other research analysts also recently commented on EXAS. Vetr raised shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $36.13 price target for the company in a report on Wednesday, May 10th. Cowen and Company raised their price target on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, May 15th. Jefferies Group LLC reissued a “buy” rating and issued a $35.00 price target on shares of Exact Sciences Corporation in a report on Tuesday, May 16th. Benchmark Co. raised their price target on shares of Exact Sciences Corporation from $34.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, May 31st. Finally, Robert W. Baird reissued an “outperform” rating and issued a $40.00 price target on shares of Exact Sciences Corporation in a report on Thursday, June 1st. Six equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Exact Sciences Corporation presently has an average rating of “Buy” and an average target price of $40.98.

Shares of Exact Sciences Corporation (NASDAQ EXAS) traded down 1.23% on Thursday, hitting $42.46. 1,698,643 shares of the stock traded hands. The stock has a 50-day moving average price of $39.48 and a 200 day moving average price of $31.77. Exact Sciences Corporation has a 52 week low of $13.05 and a 52 week high of $43.29. The firm’s market cap is $5.06 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The firm had revenue of $57.65 million during the quarter, compared to the consensus estimate of $47.73 million. Equities research analysts predict that Exact Sciences Corporation will post ($1.18) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/09/exact-sciences-corporation-exas-earns-buy-rating-from-canaccord-genuity.html.

In other news, Director Thomas D. Carey acquired 2,500 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were purchased at an average price of $37.71 per share, for a total transaction of $94,275.00. Following the completion of the transaction, the director now owns 60,858 shares of the company’s stock, valued at $2,294,955.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP D Scott Coward sold 1,987 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $35.21, for a total transaction of $69,962.27. Following the completion of the transaction, the senior vice president now owns 57,603 shares in the company, valued at approximately $2,028,201.63. The disclosure for this sale can be found here. Insiders sold 129,291 shares of company stock worth $5,288,181 in the last 90 days. Corporate insiders own 4.00% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Fortaleza Asset Management Inc. purchased a new position in shares of Exact Sciences Corporation in the second quarter valued at about $106,000. Krilogy Financial LLC increased its position in shares of Exact Sciences Corporation by 1,460.0% in the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in shares of Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 600 shares during the period. Financial Architects Inc increased its position in shares of Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock valued at $152,000 after acquiring an additional 2,035 shares during the period. Finally, Johnson Financial Group Inc. increased its position in shares of Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 1,000 shares during the period. Hedge funds and other institutional investors own 85.22% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.